INTRODUCTION
============

Liver fibrosis is a chronic disease state that typically results from dysfunctional wound healing in response to tissue injury \[[@B1]\]. Historically, liver fibrosis is believed to be a passive and irreversible process because of the collapse of the hepatic parenchyma and its substitution with a collagen-rich tissue \[[@B2]\]. Liver fibrosis, which is the common response of the liver to toxins, viral infections, drugs and various metabolic agents, is characterized by excessive accumulation of extracellular matrix (ECM) ultimately leading to cirrhosis and cancer \[[@B3]\]. Overproduction and irregular deposition of ECM in liver tissues leads to the distortion of hepatic microstructure and liver dysfunction. Thus, fibrotic stage is very important in the progress of liver disease \[[@B4]\].

Hepatic stellate cells (HSCs), the key cell type involved in liver fibrosis, normally exist in a quiescent state. Upon activation, HSCs undergo phenotypic changes that lead to secretion of an ECM scar for protection against liver damage. However, if the liver does not recover, this proceeds to liver fibrosis, cirrhosis and cancer. Therefore, it is important to induce the apoptosis of HSCs or prevent the secretion of the ECM by HSCs \[[@B5][@B6]\]. It is well known that the thioacetamide (TAA)-induced hepatic fibrosis experimental model resembles human liver fibrosis with respect to hemodynamics, morphology and biochemical metabolism, that it is also similar to virus-induced cirrhosis \[[@B7]\]. Many chronic liver diseases share the pathological process of hepatic fibrosis.

*Orostachys japonicus* (*O. japonicus*) A. Berger (Crassulaceae) is a traditional medicinal herb that grows in the barren soil of mountains or roof tiles. In traditional Asian medicine, *O. japonica* is used to reduce swelling, pain, and bleeding, as well as in the treatment of hematemesis, epistaxis, acute infectious type non-jaundice, hepatitis, malaria, bladder stones, gonorrhea, eczema and pneumonia \[[@B8][@B9]\]. Pharmacologically, *O. japonicus* has been reported to possess anti-oxidant \[[@B10]\], anti-microbial \[[@B11]\], hypolipidemic and hypoglycemic effects \[[@B12]\]. However, there is currently no scientific evidence of the anti-hepatofibrotic effects of *O. japonica*. Thus, in the present study, we investigated the anti-fibrotic effects of *O. japonica* extracts in an *in vitro* system using HSCs and *in vivo* using a TAA-induced hepatic fibrosis rat model.

MATERIALS AND METHODS
=====================

Materials
---------

Silymarin, hydroxyproline, p-dimethylaminobenzaldehyde,1,1, 3,3-tetraethoxypropane (TEP), chloramines-T, 5,5-dithiobis-2-nitrobenzoic acid (DTNB), glutathione (GSH), β-nicotinamide adenine dinucleotide phosphate, reduced form (β-NADPH), TAA and other reagents were purchased from Sigma, St. Louis, MO, USA. Dulbecco\'s modified Eagle\'s medium (DMEM) and fetal bovine serum (FBS) were acquired from Invitrogen (Carlsbad, CA, USA). Perchloric acid was obtained from GFS Chemical Co. (Columbus, OH, USA). A GOT-GPT assay kit was purchased from Asan Pharmaceutical (Hwaseong-si, Korea). Annexin V-FITC and PI Apoptosis Detection Kit I were acquired from BD Biosciences (San Jose, CA, USA). All other reagents used in this study were of the highest grade available commercially.

Plant material and extraction
-----------------------------

The plant material of *O. japonica* collected from June-July, 2016, was purchased from Chinese Medicinal Plant Co., Jecheon, South Korea. For extraction, dried *O. japonica* (100 g) was ground to a fine powder and extracted with 1 L ethanol (95%) using Soxhlet\'s extraction technique for three days. The extract was then concentrated in a vacuum under reduced pressure and lyophilized. The final yield of the lyophilized *O. japonica* extract (OJE) was 22.5% (w/w). The lyophilized OJE was stored at 4℃ until use. Prior to use, the lyophilized OJE was dissolved in 10% dimethyl sulfoxide (DMSO; Junsei Chemical Co., Ltd., Tokyo, Japan) and filtered through a 0.22 µM syringe filter, after which it was stored as a stock until use in each experiment. The final concentration of DMSO used for the study was not more than 0.1%.

Cell lines and culture
----------------------

The immortalized rat Hepatic Stellate Cell lines (HSC-T6) were received from Prof. Chang-Gue Son (Korean Hospital of Daejeon University, Daejeon, Korea). The Chang liver cell line was purchased from the American Type Culture Collection (Manassas, VA, USA). HSC-T6 cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS and 1% antibiotic-antimycotic (Invitrogen) in a humidified atmosphere of 5% CO~2~ at 37℃. The Chang liver cell line was used as a normal human cell line derived from normal liver tissue. The cells were cultured in DMEM supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA) and 1% antibiotic-antimycotic in a humidified atmosphere of 5% CO~2~ at 37℃. For activation, HSCT6 cells were serum starved before treatment with OJE

Primary HSCs isolation and culture
----------------------------------

Hepatic stellate cells were isolated from 7-week-old male Sprague Dawley (SD) rats by *in situ* pronase, collagenase perfusion, and single-step Histogenz gradient as previously described \[[@B13][@B14]\]. Isolated HSCs were cultured in DMEM containing 10% FBS and 1% antibiotic-antimycotic maintained in a humidified atmosphere of 5% CO~2~ at 37℃. Growth medium was changed on a daily basis for 7 days.

Cell viability assay
--------------------

Cell viability in HSC-T6 cells was measured using the 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) method. HSC-T6 (6 × 10^5^ cells/well) were cultured in a 96-well plate with DMEM containing 10% FBS and 1% antibiotic-antimycotic (Invitrogen, Carlsbad, CA, USA) maintained in a humidified atmosphere of 5% CO~2~ at 37℃. Next, HSC-T6 cells were treated with various concentrations of OJE (0, 0.01, 0.1, 0.5, 1.0 mg/mL) for 24 h. Cells were then incubated with 0.5 mg/mL MTT for 3 h, after which the reaction was interrupted by DMSO. The extent of reduction of MTT to formazan was measured using an ELISA reader at an optical density of 540 nm based on comparison to the viabilities of the control cells.

Cell cycle analysis
-------------------

HSC-T6 cells (1.5 × 10^6^ cells/well) were cultured in DMEM containing 10% FBS and 1% antibiotic-antimycotic maintained in a humidified atmosphere of 5% CO~2~ at 37℃. Growth medium was changed on a daily basis for 7 days. For cell cycle analysis, sample materials of OJE 0.1 and 0.5 mg/mL were evaluated for 24 h at 37℃ in an atmosphere of 5% CO~2~ and 95% humidity. Cells were then washed with PBS twice, labelled with 1 mL cold propidium iodide (PI) solution (50 µg/mL PI and 100 µg/mL RNase A) and incubated on ice for 30 min in the dark. Data were analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA).

Apoptosis analysis
------------------

HSC-T6 cells were treated with OJE (0.1 and 0.5 mg/mL) and silymarin (0.05 mg/mL) for 24 h and harvested for apoptosis assay by using Annexin V-FITC and PI Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA) according to the manufacturer\'s instructions. Data were analyzed using the BD CellQuest software (BD Biosciences, San Jose, CA, USA), which allowed assessment of specific populations. Individualization by gates was conducted according to size (FSC), granularity (SSC), and fluorescent (FL) parameters. Both early apoptotic (Annexin V^+^ and PI^-^) and late apoptotic (Annexin V^+^ and PI^+^) cells were included in cell death determinations.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

Total RNA was extracted from liver tissue samples and HSC-T6 cells using TRIzol reagent (Qiagen, Valencia, CA, USA). cDNA was synthesized from total RNA (2 µg) in a 20 µL reaction using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster, CA, USA). The primers for α-smooth muscle actin (α-SMA), collagen type1 alpha 1 (Col1α1), transforming growth factor β1 (TGF-β1), and β-actin were as follows. α-SMA (forward sequence, 5′-AACACGGCATCATCACCAACT-3′; reverse sequence, 5′-TTTCTCCCGGTTGGCCTTA-3′, Col1α1 (forward sequence, 5′-CCCAGCGGTGGTTATGACTT-3′; reverse sequence, 5′-GCTGCGG ATGTTCTCAATCTG-3′), TGF-β1 (forward sequence, 5′-AGGAGA CGGAATACAGGGCTTT-3′; reverse sequence, 5′-AGC AGGAAGGG TCGGTTCAT-3′), β-actin (forward sequence, 5′-CTAAGGCCAACC GTGAAAAGAT-3′; reverse sequence, 5′-GACCAGAGGCATACAGG GACAA-3′). The processes of reactions were conducted according to the manufacturer\'s instructions. For analysis of data, the gene expression levels were compared with those of β-actin as a reference gene.

Animals
-------

Six week old specific-pathogen-free male SD rats (six-weeks old, 190-210 g) were purchased from a commercial animal breeder (Orient Bio, Seongnam, Korea). The animals were housed in conventional cages under controlled temperature (23 ± 3℃), relative humidity (50 ± 20%) and a 12 h light/dark cycle with free access to food and water. Animals were allowed to acclimatize for at least one week before use. All animal experiments were approved by the Committee of Laboratory Animals according to the Institutional Guidelines of Konkuk University, Republic of Korea (IACUC No. KU15017).

Experimental design
-------------------

Rats were randomly divided into the following five groups of eight animals each: control group (injected with normal saline intra-peritoneally (*i.p*)), TAA group, OJE 10 (TAA with OJE 10 mg/kg), OJE 50 (TAA with OJE 50 mg/kg), and positive control silymarin group (TAA with 50 mg/kg silymarin). TAA (200 mg/kg) was injected (*i.p*) twice a week for 13 weeks to four groups except control group. OJE (10 or 50 mg/kg), silymarin (50 mg/kg), or vehicle (sterile distilled water) was administered by gastric gavage two times per week from week 7 to 13. After the last treatments, animals were fasted for 18 h, after which blood was collected by cardiac puncture under CO~2~ anesthesia. Liver tissues were removed and stored at -80℃ until use for measurement of the expression of hydroxyproline, GSH, and fibrosis-related mediated genes. A portion of the liver tissue was fixed in Bouin\'s solution for histo-morphological findings and another small portion was fixed in RNAlater solution for gene expression studies.

Serum biochemical analysis
--------------------------

On the final day of the experiment, blood samples were collected into heparinized tubes via cardiac puncture under CO~2~ anesthesia. Blood was immediately processed by centrifugation at 3,500 g for 15 min. Next, serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) were measured by spectrophotometry using a commercially available GOT-GPT assay kit (Asan Pharmaceutical, Hwaseong-si, Korea).

Determination of total glutathione (GSH) contents in liver tissues
------------------------------------------------------------------

We measured the levels of GSH using a spectrophotometer according to Ellman\'s method \[[@B15]\]. Briefly, a 50 µL sample of homogenate (or GSH standard) was combined with 80 µL of freshly prepared DTNB/NADPH mixture (10 µL 4 mM DTNB and 70 µL 0.3 mM NADPH) in a 96-well plate. Finally, 20 µL (0.06 U) of GSH reductase solution was added to each well and the absorbance was recorded at 412 nm after 5 min. The amount of GSH was expressed as mM of GSH per gram of tissue.

Determination of hydroxyproline in liver tissues
------------------------------------------------

Hydroxyproline determination was conducted as previously described, with some modifications \[[@B16]\]. Briefly, liver tissues were homogenized with dilution buffer. Hydrolysis was performed by adding 1 mL of 6N HCl to 2 mL of liver homogenate in a tightly capped glass tube and then incubating samples overnight at 100℃. After cooling, the acid hydrolysates were filtered through a 0.45 µm filter paper (Toyo Roshi Kaisha, Tokyo, Japan). Next, 50 µL samples or hydroxyproline standards in 6N HCl were air-dried and dissolved in methanol (50 µL), after which 1.2 mL of 50% isopropanol and 200 µL of chloramine-T solution were added to each sample, which was followed by incubation at room temperature for 10 min. Ehrlich\'s solution (1.3 mL) was then added, after which the samples were incubated at 50℃ for 90 min and the optical density of the reaction product was read at 558 nm using a spectrophotometer (Sunrise, Tecan, San Jose, CA USA). Concentrations were then determined based on comparison to a standard curve constructed using serial dilutions of 0.5 mg/mL hydroxyproline solution.

Histopathology of liver tissue
------------------------------

Liver tissues were fixed in Bouin\'s solution and then embedded in paraffin, after which paraffin sections of 5 µm thickness were stained with hematoxylin and eosin (H & E) and Masson\'s trichrome. For identification and analysis of collagen expression, the blue-stained areas in the Masson\'s trichrome stained sections were measured using an image analyzer (Image J, NIH, Bethesda, MD, USA).

Statistical analysis
--------------------

All results are expressed as the means ± standard error of the mean (SEM, n = 8). Differences between groups were identified using one-way analysis of variance (ANOVA) followed by a Student\'s *t*-test. A value of *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Effect of OJE on the cell viability and primary HSC morphology
--------------------------------------------------------------

We first assessed the effect of various concentrations (0, 0.01, 0.1, 0.5 and 1.0 mg/mL) of OJE on cell viability in HSC-T6 cells and Chang liver cells. As shown in [Fig. 1A](#F1){ref-type="fig"}, OJE administered at concentrations of up to 0.5 mg/mL did not show induce any significant changes in the overall cell viability or generate toxicity in HSC-T6 cells or Chang liver cells. However, 1.0 mg/mL induced significant changes, negatively affecting the overall cell viability. Furthermore, the solvent used to dissolve the OJE extract, DMSO (0.1%), also did not show any toxicity toward HSC-T6 and Chang liver cells. Therefore, all *in vitro* experiments were conducted using OJE 0.1 and/or 0.5 mg/mL as the concentrations were considered non-toxic and effective ([Fig. 1A](#F1){ref-type="fig"}).

As shown in [Fig. 1B](#F1){ref-type="fig"}, untreated activated HSCs showed normal morphology (day 7). Moreover, treatment of 8 day-cultured primary HSCs with OJE at 0.5 mg/mL (high non-toxic concentration) for 24 h reduced collagen fiber morphology and decreased the number of viable HSCs. Further, decreased stretched fibers were observed after 24 h when compared to untreated activated HSCs. Taken together, these findings clearly indicate that OJE influenced the morphology of the cultured activated HSCs ([Fig. 1C](#F1){ref-type="fig"}).

Effect of OJE on cell cycle and apoptosis in HSC-T6 cells
---------------------------------------------------------

As shown in [Fig. 2](#F2){ref-type="fig"}, flow cytometric analysis of OJE treated HSC-T6 cells showed marked effects. Specifically, treatment with 0.1 mg/mL and 0.5 mg/mL OJE resulted in 1.79% and 2.55% of the cells compared with control cells showing a distribution of 1.08% in the sub-G1 phase. Additionally, treatment with silymarin resulted in 1.65% of the cells being in the sub-G1 phase. To verify the apoptosis effect of OJE, HSC-T6 cells were treated with silymarin (0.05 mg/mL) and OJE (0.1 and 0.5 mg/mL) for 24 h. As indicated by the Annexin V-FITC/PI assay, OJE and silymarin significantly increased apoptosis in HSC-T6 cells when compared with the control group ([Fig. 3A-3D](#F3){ref-type="fig"}). The percentage of cells undergoing apoptotic cell death increased from 9.09 ± 1.54 to 25.87 ± 3.65 in the silymarin group, while it was 27.48 ± 1.89 in the 0.5 mg/mL OJE treated group and 16.95 ± 3.01% in the 0.1 mg/mL OJE treated group at 24 h. When compared with the Annexin V positive cells in the control group, OJE (0.5 mg/mL) and silymarin (0.05 mg/mL) induced three and two fold increases in Annexin V positive cells, respectively ([Fig. 3E](#F3){ref-type="fig"}). Taken together, these results show that OJE significantly (*P* \< 0.01) induced cell death and apoptosis in HSC-T6 cells.

Effect of OJE on fibrosis related gene expression in HSC-T6 cells
-----------------------------------------------------------------

The expression of genes associated with fibrosis such as TGF-β, α-SMA and Col1α1 were measured to verify the effects of OJE on HSC-T6 cells. As shown in [Fig. 3F](#F3){ref-type="fig"}, TGF-β, α-SMA and Col1α1 expression were significantly down-regulated in the OJE (0.1 and 0.5 mg/mL) treatment groups when compared with the control group. The positive control silymarin also exhibited significant effects by regulating the fibrosis mediated gene suppression that were similar to the effects of the OJE 0.5 mg/mL treated group.

Effect of OJE on serum biochemical properties of TAA-induced fibrosis in rats
-----------------------------------------------------------------------------

TAA treatment significantly elevated the serum ALT and AST levels when compared with the control group ([Fig. 4A and 4B](#F4){ref-type="fig"}). The elevated levels of ALT and AST were significantly attenuated by OJE at both concentrations (10 and 50 mg/kg) when compared with TAA-induced group. Silymarin also exhibited a significant effect when compared with control treated groups.

Effect of OJE on the GSH content in TAA-induced liver tissues
-------------------------------------------------------------

As shown in [Fig. 4C](#F4){ref-type="fig"}, TAA treatment significantly decreased (*P* \< 0.001) the GSH contents in the liver tissue when compared with the control group. However, OJE (10 and 50 mg/kg) treatment significantly (*P* \< 0.01) attenuated this decrease in GSH contents, as did treatment with the positive control silymarin (*P* \< 0.001). These findings indicate that TAA causes liver injury through reactive oxygen species (ROS) damage, which is associated with antioxidant enzymes, and that OJE significantly ameliorated these changes.

Effect of OJE on the hydroxyproline content in TAA-induced liver tissues
------------------------------------------------------------------------

The hydroxyproline content in TAA-induced liver tissue was significantly (*P* \< 0.001) increased in the TAA group compared to the normal group. However, OJE (10 and 50 mg/kg) treatment significantly reduced hydroxyproline levels compared with the TAA group ([Fig. 4D](#F4){ref-type="fig"}). The silymarin treatment also reduced hydroxyproline content in TAA-induced liver tissue.

Effect of OJE on the TAA-induced histopathology of liver tissues
----------------------------------------------------------------

As shown in [Fig. 5A](#F5){ref-type="fig"}, the control group showed normal morphology upon H & E staining. However, TAA treatment led to severe pathological alterations, such as a shrunken, solidified and abnormally patterned liver ([Fig. 5B](#F5){ref-type="fig"}). These alterations were dramatically attenuated by OJE (10 and 50 mg/kg) and silymarin treatment ([Fig. 5C-5E](#F5){ref-type="fig"}). Further, Masson\'s trichrome showed severe collagen accumulation (part of the blue staining) in the TAA group, while the OJE (10 and 50 mg/kg) treated groups remarkably protected against collagen accumulation ([Fig. 6A-6E](#F6){ref-type="fig"}). The percentage area of fibrosis revealed significant damage in the TAA treated group when compared with the control group. However, treatment with OJE at both concentrations and silymarin ameliorated these changes significantly (*P* \< 0.001 and *P* \< 0.01, respectively) when compared with TAA treated group ([Fig. 6F](#F6){ref-type="fig"}).

Effect of OJE on the fibrosis related gene expression in the TAA-induced liver tissues
--------------------------------------------------------------------------------------

Fibrosis associated genes expression in the liver tissue was analyzed using qRT-PCR. TAA treatment up-regulated the gene expression of TGF-β, α-SMA and Col1α1, while OJE (50 mg/kg) and positive control silymarin treated groups down-regulated the expression of all genes tested ([Fig. 7A-7C](#F7){ref-type="fig"}). However, OJE treatment at 10 mg/kg did not influence the TAA-induced changes in α-SMA expression ([Fig. 7B](#F7){ref-type="fig"}). Further, treatment with silymarin exhibited superior effects at down regulating the expression of fibrotic associated genes than OJE, which was in agreement with the *in vitro* data.

DISCUSSION
==========

The liver is an organ of paramount importance that plays a major role in regulating various physiological processes including metabolism, excretion and regulation of glycogen storage in the body. Fibrosis of the liver is a reversible complication of advanced hepatic disease that represents a major burden in health care. Hepatic stellate cells (HSCs), which are the major cell type involved in the production of ECM in the liver, undergo activation into proliferative and fibrogenic myofibroblast-like cells during liver injury \[[@B7]\]. Dysregulation in the proliferation and apoptosis of HSC is known to be involved in the pathogenesis of liver fibrosis; therefore, inhibiting HSC activation and inducing apoptosis has become an ideal approach to preventing or treating hepatic fibrosis \[[@B7][@B17][@B18]\]. In the present study, OJE inhibited HSC proliferation, induced apoptosis and altered the morphology of HSCs *in vitro*. Further, OJE (0.5 mg/mL) down regulated the gene expression of TGF-β, α-SMA, and Col1α1, selective markers of HSCs activation.

In *in vivo* studies, liver fibrosis is commonly induced with thioacetamide, which is readily metabolized to reactive acetamide and TAA-S-oxide. These metabolites react with hepatic tissue, leading to the accumulation of fatty acids, DNA/protein damage and formation of reactive oxygen species (ROS). The major changes observed in TAA-induced liver damage are altered serum liver enzymes such as AST and ALT \[[@B19][@B20]\]. In this study, the TTA-induced increase in the levels of AST and ALT enzymes was significantly reduced by OJE treatment. Furthermore, the ROS generated by the metabolites of TAA led to progression of liver damage and reduced the levels of antioxidant enzymes such as GSH \[[@B21]\]. Therefore, restoring GSH content might be helpful to the treatment of TAA-induced oxidative liver damage. Accumulation of ECM is a common phenomenon in liver fibrosis, and hydroxyproline, a major constituent of collagen, is a good marker of ECM accumulation \[[@B22][@B23]\]. In the present study, OJE markedly restored the GSH content and decreased the hydroxyproline level, indicating that this compound inhibited ROS generation and ECM accumulation, thereby suppressing hepatic fibrosis.

Earlier reports indicated that inhibition of the TGF-β1 signaling pathway attenuates liver fibrosis. Signaling of TGF-β family members is mediated by TGFβR, which phosphorylates downstream receptor-activated Smads, which are considered specific markers for smooth muscle cell differentiation \[[@B24][@B25]\]. Further, TGF-β produced by Kupffer cells and HSCs, up regulates transcription of the collagen genes Col1α1 and Col1α2, which are observed in damaged liver and highly expressed in activated HSCs from cirrhotic liver \[[@B26]\]. Therefore, we tested the effects of OJE on the expression of genes involved in fibrotic mediation such as of TGF-β, Col1α1 and α-SMA in rat liver tissues induced by TAA. In agreement with our *in vitro* data, OJE significantly suppressed the TAA-induced increase in the expression of TGF-β, Col1α1 and α-SMA in rat liver tissues. These results indicate that the antifibrotic action of OJE might be partially mediated via inhibition of the TGF-β1/Smad pathway. Further, histopathological studies revealed that TAA intoxication produced substantial liver fibrosis and prominent regenerative nodule development, resulting in features of degeneration, necrosis and elements of fibrosis \[[@B27]\]. These alterations in TAA-induced morphological features were attenuated by OJE.

*O. japonicus* is an important health promoting herb with rich nutritional values \[[@B12]\]. Reports have indicated the presence of numerous bioactive constituents including dietary flavonoids (quercetin and kaempferol), fatty acid esters, triterpenoids, 4-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, and gallic acid \[[@B28][@B29][@B30]\]. Some of these compounds, such as quercetin, kaempferol and gallic acid, were reported to possess strong hepatoprotective properties including anti-fibrotic effects \[[@B31][@B32][@B33]\]. The compounds present in the OJE might act synergistically in delivery of potent anti-hepatofibrotic effects.

In conclusion, OJE exhibited potential anti-fibrotic effects by increasing the apoptosis and inhibition of ECM accumulation in HSC-T6 cells. Furthermore, OJE ameliorated the TAA-induced liver fibrosis *in vivo* in a rat model. Regulation of the TGF-β 1/Smad pathway and anti-oxidative potential might partly be the mechanistic basis for the potent effects shown by OJE as an anti-hepatoprotective agent. The results of the present study provide scientific evidence for the traditional claims of the usefulness of OJE to treat liver disorders. Based on these observations, we suggest that further studies be conducted to investigate development of *O. japonicus* as a potential nutritional supplement against toxin and oxidative stress mediated liver fibrosis.
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![Cell viability assay of HSC-T6/Chang liver cells and morphological changes in primary HSCs in response to treatment with OJE.\
(A) HSC-T6 and Chang liver cells were incubated with OJE at the indicated concentrations for 24 h, after which the cell viability was determined by MTT assay. Primary HSCs were cultivated for 1 week (B) and exposed to OJE at 0.5 mg/mL for 24 h (C). Pictures were taken before and after 24 h of treatment with OJE. Magnification was 100×. Arrows indicate HSCs. The data are expressed as the means ± SEM (n = 8), which were compared using one-way analysis of variance (ANOVA) followed by Student\'s *t*-test. NS, not significant and ^\*\*\*^*P* \< 0.001 compared to the control group. OJE, *O. japonica* extract; HSC, hepatic stellate cells; DMSO, dimethyl sulfoxide.](nrp-11-470-g001){#F1}

![Effect of OJE on the cell cycle in HSC-T6 cells.\
DNA contents in different phases of the cell cycle were measured by flow cytometry using propidium iodide. The cell cycle distribution for each treatment group and the percentage of the cell cycle distribution are represented by graphs (A) and histogram (B), respectively. OJE: *O. japonica* extract.](nrp-11-470-g002){#F2}

![Effect of OJE on apoptosis and fibrosis expression in HSC-T6 cells.\
A: Control cells. Flow cytometric data indicate apoptosis in HSC-T6 cells after incubation with silymarin (B), OJE 0.5 mg/mL (C), or OJE 0.1 mg/mL (D) for 24 h. E: Data show the apoptotic (Annexin V^+^ and PI^-^) and late apoptotic (Annexin V^+^ and PI^+^) cells. F: Fibrosis related gene expression. The data are presented as the means ± SEM (n = 8) which were compared using one-way analysis of variance (ANOVA) followed by Student\'s *t*-test. \* *P* \< 0.05 and \*\* *P* \< 0.01 compared to the control group. OJE: *O. japonica* extract.](nrp-11-470-g003){#F3}

![Effect of OJE on AST/ALT levels, total glutathione (GSH) contents and hydroxyproline levels in TAA-induced liver fibrosis rats.\
A: HSC-T6 cells were incubated with 10 and 50 mg/mL OJE for 24 h. Expression of fibrosis related genes in HSC-T6 cells was determined by real-time PCR. The results are expressed as normalized fold values relative to the control. Levels of ALT (A) and AST (B) in serum were measured by spectrophotometry. (C) Total GSH contents in liver tissue (D) and hydroxyproline levels of TAA-induced liver tissue of rats were measured using spectrophotometry. TAA, thioacetamide-induced liver fibrosis rats; Silymarin, positive control rats; OJE 10, TAA plus OJE 10 mg/kg treated rats; OJE 50, TAA plus OJE 50 mg/kg treated rats. Data are expressed as means ± SEM (n = 8) which were compared using one-way analysis of variance (ANOVA) followed by Student\'s *t*-test. ^\#\#\#^*P* \< 0.001 compared to the control group, ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared with TAA group. OJE, *O. japonica* extract; TAA, thioacetamide; ALT, alanine transaminase; AST, aspartate transaminase; GSH, glutathione.](nrp-11-470-g004){#F4}

![Effect of OJE on TAA-induced morphology of liver tissues by Hematoxylin and Eosin (H&E) staining.\
At the end of the experiment, all animals were sacrificed and livers were fixed in Bouin\'s solution. After staining with H&E, liver sections were observed by light microscopy. Control, naive rats (A); TAA, TAA-induced liver fibrosis rats (B); Silymarin, Positive control rats (C); OJE 50, TAA plus OJE 50 mg/kg treated rats (D); OJE 10, TAA plus OJE 10 mg/kg treated rats (E). Scale bar = 200 µm. OJE, *O. japonica* extract; TAA, thioacetamide.](nrp-11-470-g005){#F5}

![Effect of OJE on TAA-induced fibrosis by Masson\'s trichrome staining of liver tissues.\
This stain was performed as described for H&E staining. Control, naive rats (A); TAA, TAA-induced liver fibrosis rats (B); Silymarin, Positive control rats (C); OJE 50, TAA plus OJE 50 mg/kg treated rats (D); OJE 10, TAA plus OJE 10 mg/kg treated rats. Percentage of fibrosis area plot (F). Scale bar = 200 µm. Quantification was accomplished using ImageJ. Values are presented as the means ± SEM (n = 8) which were compared using one-way analysis of variance (ANOVA) followed by Student\'s *t*-test. ^\#^*P* \< 0.05 compared to the control group, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared to the TAA group. TAA, Thioacetamide; OJE, *O. japonica* extract.](nrp-11-470-g006){#F6}

![Effect of OJE on fibrosis related gene expression in TAA-induced liver tissues.\
Expression of fibrosis related genes in liver tissue was measured by real-time PCR. (A) TGF-β, (B) α-SMA, (C) Col1α1. The results are expressed as normalized fold values relative to the control. Values are presented as the means ± SEM (n = 8) which were compared using one-way analysis of variance (ANOVA) followed by Student\'s *t*-test. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 compared to the TAA group. TAA, Thioacetamide; OJE, *O. japonica* extract; α-SMA, alpha-smooth muscle actin; Col1α1, collagen type1 alpha 1; TGF-β1, transforming growth factor β1.](nrp-11-470-g007){#F7}
